Literature DB >> 12645649

Karyotypic abnormalities in myelofibrosis following polycythemia vera.

Joris Andrieux1, Jean Loup Demory, Marie Thérèse Caulier, Philippe Agape, Marc Wetterwald, Francis Bauters, Jean Luc Laï.   

Abstract

Polycythemia vera (PV) is a chronic myeloproliferative disease characterized by an increase of total red cell volume; in 10% to 15% of cases, bone marrow fibrosis complicates the course of the disease after several years, resulting in a hematologic picture mimicking myelofibrosis with myelocytic metaplasia (MMM). This condition is known as post polycythemic myelofibrosis (PPMF). Among 30 patients with PPMF followed in Northern France, 27 (90%) expressed one or two abnormal clones in myelocytic cell cultures. Of these, 19 (70%) had partial or complete trisomy 1q. This common anomaly either resulted from unbalanced translocations with acrocentric chromosomes, that is, 13, 14, and 15, or other chromosomes, that is, 1, 6, 7, 9, 16, 19, and Y, or from partial or total duplication of long arm of chromosome 1. A single patient had an isochromosome 1q leading to tetrasomy 1q. In all cases, a common trisomic region spanning 1q21 to 1q32 has been identified. Given that most patients had previously received chemotherapy or radio-phosphorus to control the polycythemic phase of their disease, this study illustrates the increased frequency of cytogenetic abnormalities after such treatments: 90% versus 50% in de novo MMM. Moreover, karyotype can be used to distinguish PPMF-where trisomy 1q is the main anomaly-from primary MMM where trisomy 1q is rare and deletions 13q or 20q are far more common. Whether trisomy 1q is or is not a secondary event remains a matter of debate, as well as the role of cytotoxic treatments.

Entities:  

Mesh:

Year:  2003        PMID: 12645649     DOI: 10.1016/s0165-4608(02)00678-7

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

1.  Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.

Authors:  Bridget K Marcellino; Ronald Hoffman; Joseph Tripodi; Min Lu; Heidi Kosiorek; John Mascarenhas; Raajit K Rampal; Amylou Dueck; Vesna Najfeld
Journal:  Blood Adv       Date:  2018-12-26

2.  Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.

Authors:  Bridget S Wilkins; Deepti Radia; Claire Woodley; Sarah El Farhi; Clodagh Keohane; Claire N Harrison
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

3.  A Rare Presentation of Extramedullary Hematopoiesis in Post-polycythemic Myelofibrosis.

Authors:  Ceyla Konca Degertekin; Zübeyde Nur Ozkurt; Nalan Akyürek; Münci Yağcı
Journal:  Indian J Hematol Blood Transfus       Date:  2012-12-07       Impact factor: 0.900

Review 4.  Leukemia secondary to myeloproliferative neoplasms.

Authors:  Andrew J Dunbar; Raajit K Rampal; Ross Levine
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 5.  Genetic Background of Polycythemia Vera.

Authors:  Mathilde Regimbeau; Romain Mary; François Hermetet; François Girodon
Journal:  Genes (Basel)       Date:  2022-04-02       Impact factor: 4.141

6.  Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies.

Authors:  I Gómez-Seguí; H Makishima; A Jerez; K Yoshida; B Przychodzen; S Miyano; Y Shiraishi; H D Husseinzadeh; K Guinta; M Clemente; N Hosono; M A McDevitt; A R Moliterno; M A Sekeres; S Ogawa; J P Maciejewski
Journal:  Leukemia       Date:  2013-06-14       Impact factor: 11.528

Review 7.  The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.

Authors:  Torsten Haferlach; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Journal:  Ann Hematol       Date:  2007-10-16       Impact factor: 3.673

Review 8.  Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.

Authors:  Julian Baumeister; Nicolas Chatain; Alexandros Marios Sofias; Twan Lammers; Steffen Koschmieder
Journal:  Cells       Date:  2021-12-16       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.